Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 1.64M 1.44M 1.34M 1.23M 2.32M 157M 2.35M 15.96M 6.23M 77.68M 6.16M 6.03M 268M P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 8.13M 7.15M 6.65M 6.11M 11.47M 780M 11.62M 79.07M 30.88M 385M 30.52M 29.86M 1.33B EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0
5 years 0
Extreme 0
0
10 years 0
Extreme 0
0
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%-.--%-.--% 3.65K
+0.13%+4.41%+47.35%+163.20% 1,068B
+0.97%+6.88%+58.02%+53.12% 641B
-0.94%+1.39%+35.02%+72.60% 454B
+0.12%+8.36%+38.80%+34.26% 351B
+0.02%+2.85%+38.33%+43.07% 299B
-0.97%+2.51%+18.68%+15.81% 266B
+0.57%+1.36%-27.20%-37.84% 220B
+0.06%+3.32%+22.73%+59.40% 203B
+0.94%-2.02%+12.32%+70.59% 162B
Average -4.47%+2.48%+24.41%+47.42% 366.33B
Weighted average by Cap. +0.86%+2.85%+36.67%+77.95%

Financials

2007 2008
Net sales 23.47M 20.63M 19.2M 17.64M 33.12M 2.25B 33.55M 228M 89.15M 1.11B 88.09M 86.19M 3.84B 25.96M 22.82M 21.24M 19.51M 36.63M 2.49B 37.12M 253M 98.62M 1.23B 97.45M 95.35M 4.25B
Net income -20.86M -18.34M -17.07M -15.68M -29.43M -2B -29.82M -203M -79.24M -988M -78.3M -76.61M -3.41B -4.01M -3.52M -3.28M -3.01M -5.65M -384M -5.73M -38.96M -15.22M -190M -15.04M -14.71M -656M
Net Debt 18.79M 16.52M 15.38M 14.12M 26.52M 1.8B 26.87M 183M 71.38M 890M 70.54M 69.02M 3.08B 6.49M 5.7M 5.31M 4.88M 9.16M 622M 9.28M 63.11M 24.65M 307M 24.36M 23.83M 1.06B
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
155
  1. Stock Market
  2. Stocks
  3. SYVC Stock